Dosing & Uses
Nonalcoholic Steatohepatitis
Pending FDA approval for nonalcoholic steatohepatitis (NASH)
Next:
Pharmacology
Mechanism of Action
Thyroid hormone receptor (THR)-β selective agonist designed to target key underlying causes of nonalcoholic steatohepatitis (NASH) in the liver
THR-β action is key to proper liver function, including regulation of mitochondrial activity, such as breakdown of liver fat and control of the level of normal, healthy mitochondria
Patients with NASH have reduced levels of THR-β receptor activity in the liver
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
